DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer

Table 2

Associate of DUOX2 mRNA expression with clinicopathological characteristics.

Variable	Group	Number of cases (%)	DUOX2 expression		value
			High	Low
Gender	Male	62 (72.1)	29	33	0.336
	Female	24 (27.9)	14	10
Age (years)Age (years)	>65	37 (43.0)	17	20	0.514
	65	49 (57.0)	26	23
Tumor diameter (cm)	>2	67 (77.9)	38	29	0.019
	2	19 (22.1)	5	14
Tumor location	Head	57 (66.3)	27	30	0.494
	Body/tail	29 (33.7)	16	13
TNM stage	I-IIA	43 (50)	15	28	0.005
	IIB-IV	43 (50)	28	15
T stage	T1	20 (23.3)	6	14	0.041
	T2-3	66 (76.7)	37	29
N stage	Absent	46 (53.5)	15	31	0.001
	Present	40 (46.5)	28	12
M stage	M0	85 (98.8)	43	42	1
	M1	1 (1.2)	0	1
Histological stage	I-II/II	31 (36)	15	16	0.822
	II-III/III	55 (64)	28	27
Serum CA-199 (kU/L)Serum CA-199 (kU/L)	39	59 (72)	31	28	0.275
	<39	23 (28)	9	14
Serum CEA (μg/L)	4.7	29 (35.4)	13	16	0.596
	<4.7	53 (64.6)	27	26
Perineural invasion	Absent	14 (16.5)	4	10	0.088
	Present	71 (83.5)	38	33

, , and .